The candidate vaccine, developed by scientists at Britain's
University of Oxford and called R21/Matrix-M, showed up to 77%
efficacy in the year-long trial of 450 children in Burkina Faso,
researchers leading the trial said in a statement.
The scientists, led by Adrian Hill, director of Oxford's Jenner
Institute and also one of the lead researchers behind the Oxford-AstraZeneca
COVID-19 vaccine, said they now plan to conduct final stage trials
in some 4,800 children aged between 5 months and 3 years in four
African Countries.
Hill said he had "high expectations for the potential of this
vaccine" which he said would be the first against malaria to reach a
World Health Organization (WHO) goal of a malaria shot with at least
75% efficacy.
Scientists around the world have been working for decades to develop
a vaccine to prevent malaria - a complex infection caused by a
parasite carried in the saliva of mosquitoes.
Malaria infects millions of people every year and kills more than
400,000 - most of them babies and young children in the poorest
parts of Africa.
[to top of second column] |
The world's first and only licensed malaria vaccine, Mosquirix, was
developed by GlaxoSmithKline over many years of clinical trial
across several African countries, but is only partially effective at
around 30%.
In the R21/Matrix-M trial in Burkina Faso, the 450 young children
were divided into three groups. Two groups got three doses of the
experimental vaccine along with either a low or a high dose of an
adjuvant - an ingredient designed to super-charge the body's
response to a vaccine - while the third group was given a control
vaccine.
Results, which researchers said would soon be published in The
Lancet medical journal, showed efficacy of 77% in the high-dose
adjuvant group and 74% among those who got the vaccine with a
low-dose of adjuvant.
(Reporting by Kate Kelland, Editing by William Maclean)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |